Home LiteratureArticle Details
PMID: 9323713 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs.

Molecular medicine (Cambridge, Mass.) ·Vol. 3 ·No. 9 ·1997-09-00 ·Pages 617-27

Stitt AW, He C, Friedman S, Scher L, Rossi P, Ong L, Founds H, Li YM, Bucala R, Vlassara H

Abstract

Advanced glycation endproducts (AGEs) are implicated in the pathogenesis of atherosclerotic vascular disease of diabetic and nondiabetic etiology. Recent research suggests that advanced glycation of ApoB contributes to the development of hyperlipidemia. AGE-specific receptors, expressed on vascular endothelium and mononuclear cells, may be involved in both the clearance of, and the inflammatory responses to AGEs. The aim of this study was to examine whether there is a relationship between serum AGE-ApoB and AGEs in arterial tissue of older normolipidemic nondiabetic patients with occlusive atherosclerotic disease, compared with age-matched and younger asymptomatic persons. Serum AGE-ApoB was measured by ELISA in 21 cardiac bypass patients. Furthermore, an AGE-specific monoclonal antibody, and polyclonal antibodies against anti-AGE-receptor (anti-AGE-R) 1 and 2 were used to explore the localization and distribution of AGEs and AGE-R immunoreactivity (IR) in arterial segments excised from these patients. Serum AGE-ApoB levels were significantly elevated in the asymptomatic, older population, compared with those in young healthy persons (259 +/- 24 versus 180 +/- 21 AGE U/mg of ApoB, p < 0.01). Higher AGE-ApoB levels were observed in those patients with atherosclerosis (329 +/- 23 versus 259 +/- 24 AGE U/mg ApoB, p < 0.05). Comparisons of tissue AGE-collagen with serum AGE-ApoB levels showed a significant correlation (r = 0.707, p < 0.01). In early lesions, AGE-IR occurred mostly extracellularly. In fatty streaks and dense, cellular atheromatous lesions, AGE-IR was visible within lipid-containing smooth muscle cells and macrophages, while in late-stage, acellular plaques, AGE-IR occurred mostly extracellularly. AGE-R1 and -R2 were observed on vascular endothelial and smooth-muscle cells and on infiltrating mononuclear cells in the early-stage lesions, whereas in dense, late-stage plaques, they colocalized mostly with lipid-laden macrophages. On tissue sections, scoring of AGE-immunofluorescence correlated with tissue AGE and plasma AGE-ApoB. (1) The correlation between arterial tissue AGEs and circulating AGE-ApoB suggests a causal link between AGE modification of lipoproteins and atherosclerosis. AGE-specific receptors may contribute to this process. (2) Serum AGE-ApoB may serve to predict atherosclerosis in asymptomatic patients.

MeSH Terms
Adult Aged Aged, 80 and over Aging Apolipoproteins B/blood Arteriosclerosis/blood,metabolism,pathology Carotid Arteries/pathology Collagen/analysis Endothelium, Vascular/chemistry,pathology Enzyme-Linked Immunosorbent Assay Female Glycation End Products, Advanced/analysis,blood Humans Immunohistochemistry Macrophages/chemistry Male Microscopy, Fluorescence Middle Aged Receptor for Advanced Glycation End Products Receptors, Immunologic/analysis,blood Regression Analysis
Chemicals
Apolipoproteins B Glycation End Products, Advanced Receptor for Advanced Glycation End Products Receptors, Immunologic Collagen
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Stitt A W
Picower Institute for Medical Research, Manhasset, New York, USA.
He C
Friedman S
Scher L
Rossi P
Ong L
Founds H
Li Y M
Bucala R
Vlassara H
References (38)
38 references, click to expand
  1. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition.
    Proc Natl Acad Sci U S A. 1979 Jan;76(1):333-7 PMID: 218198
  2. Factors regulating the activities of the low density lipoprotein receptor and the scavenger receptor on human monocyte-macrophages.
    J Lipid Res. 1981 Sep;22(7):1131-41 PMID: 6271886
  3. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody.
    Am J Pathol. 1995 Sep;147(3):654-67 PMID: 7545874
  4. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits.
    Arterioscler Thromb Vasc Biol. 1995 May;15(5):571-82 PMID: 7749871
  5. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor.
    J Biol Chem. 1995 May 5;270(18):10828-32 PMID: 7738020
  6. Protein glycation and fluorescent material in human atheroma.
    Atherosclerosis. 1994 Dec;111(2):255-65 PMID: 7718028
  7. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins.
    Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11047-52 PMID: 8855306
  8. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex.
    Mol Med. 1995 Sep;1(6):634-46 PMID: 8529130
  9. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits.
    Mol Med. 1995 May;1(4):447-56 PMID: 8521302
  10. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif.
    Nat Med. 1995 Oct;1(10):1057-61 PMID: 7489363
  11. Effects of age and diabetes mellitus on the solubility of collagen from human skin, tracheal cartilage and dura mater.
    Exp Gerontol. 1982;17(3):185-94 PMID: 7140859
  12. Covalent attachment of soluble proteins by nonenzymatically glycosylated collagen. Role in the in situ formation of immune complexes.
    J Exp Med. 1983 Nov 1;158(5):1739-44 PMID: 6415211
  13. Accelerated age-related browning of human collagen in diabetes mellitus.
    Proc Natl Acad Sci U S A. 1984 Jan;81(2):583-7 PMID: 6582514
  14. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling.
    Science. 1988 Jun 10;240(4858):1546-8 PMID: 3259727
  15. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties.
    J Exp Med. 1989 Oct 1;170(4):1387-407 PMID: 2551990
  16. Regulation of differentiated properties and proliferation of arterial smooth muscle cells.
    Arteriosclerosis. 1990 Nov-Dec;10(6):966-90 PMID: 2244864
  17. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging.
    Proc Natl Acad Sci U S A. 1990 Nov;87(22):9010-4 PMID: 2247477
  18. Nonenzymatic glycation of collagen in aging and diabetes.
    Proc Soc Exp Biol Med. 1991 Jan;196(1):17-29 PMID: 1984239
  19. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes.
    J Clin Invest. 1991 Feb;87(2):432-8 PMID: 1991829
  20. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins.
    J Exp Med. 1991 Sep 1;174(3):515-24 PMID: 1651976
  21. Advanced glycosylation end products in patients with diabetic nephropathy.
    N Engl J Med. 1991 Sep 19;325(12):836-42 PMID: 1875967
  22. Immunochemical detection of advanced glycosylation end products in vivo.
    J Biol Chem. 1992 Mar 15;267(8):5133-8 PMID: 1371995
  23. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface.
    J Biol Chem. 1992 Jul 25;267(21):14987-97 PMID: 1321822
  24. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins.
    J Biol Chem. 1992 Jul 25;267(21):14998-5004 PMID: 1378843
  25. Receptor-mediated interactions of advanced glycosylation end products with cellular components within diabetic tissues.
    Diabetes. 1992 Oct;41 Suppl 2:52-6 PMID: 1326453
  26. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM.
    Diabetes. 1992 Oct;41(10):1286-92 PMID: 1397702
  27. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications.
    Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12043-7 PMID: 1465438
  28. Collagen-linked fluorescence in human atherosclerotic plaques.
    Atherosclerosis. 1993 Jan 25;98(2):219-27 PMID: 8457261
  29. The pathogenesis of atherosclerosis: a perspective for the 1990s.
    Nature. 1993 Apr 29;362(6423):801-9 PMID: 8479518
  30. Lipid advanced glycosylation: pathway for lipid oxidation in vivo.
    Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6434-8 PMID: 8341651
  31. Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling.
    J Exp Med. 1993 Dec 1;178(6):2165-72 PMID: 8245789
  32. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus.
    Am J Pathol. 1993 Dec;143(6):1649-56 PMID: 8256853
  33. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging.
    Lab Invest. 1994 Feb;70(2):138-51 PMID: 8139257
  34. Lipoprotein-proteoglycan complexes from injured rabbit aortas accelerate lipoprotein uptake by arterial smooth muscle cells.
    Atherosclerosis. 1994 Jan;105(1):79-87 PMID: 8155089
  35. Expression of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein and scavenger receptor in human atherosclerotic lesions.
    J Clin Invest. 1994 May;93(5):2014-21 PMID: 8182133
  36. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions.
    Arterioscler Thromb. 1994 Oct;14(10):1521-8 PMID: 7918300
  37. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency.
    Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9441-5 PMID: 7937786
  38. Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines.
    J Clin Invest. 1995 Jan;95(1):122-33 PMID: 7814605
Article Info
Journal
Molecular medicine (Cambridge, Mass.)
Abbr.
Mol Med
ISSN
1076-1551
Published
1997-09-00
Pages
617-27
Language
English
Region
England
NLM ID
9501023
PMCID
PMC2230092
Subset
IM
Grants
NIA NIH HHS · AG06943 · United States
NIA NIH HHS · AG09453 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com